EN 1001
Alternative Names: EN-1001Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Enosi Life Sciences
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Oct 2024 No recent reports of development identified for research development in Cancer in USA
- 28 Oct 2024 No recent reports of development identified for research development in Inflammation in USA